Abstract
The aim was to assess whether hepatocyte growth factor (HGF) and interleukin (IL)-6 in combination with prostate volume are able to accurately detect prostate cancer in patients with gray-zone prostate-specific antigen (PSA) levels. A total of 159 patients with PSA levels of <10 ng ml−1 were enrolled. Forty-two (35.3%) were diagnosed with prostate cancer, whereas 117 (64.7%) had no cancer and were used as benign group. HGF and IL-6 density (HGFD and IL-6D, respectively) values were calculated by dividing serum HGF and IL-6 levels with prostate volume. Median IL-6 (2.3 pg ml−1) levels for the prostate cancer group were significantly higher than those for the benign group before adjustment for age (1.7 pg ml−1) (P=0.0098). After age adjustments, median IL-6 (2.17 pg ml−1), HGFD (0.00972 ng ml−1 cm−3), and IL-6D (0.0848 pg ml−1 cm−3) values for the prostate cancer group were significantly higher than those for the benign group (IL-6, 1.78 pg ml−1; HGFD, 0.00732 ng/ml/cc; and IL-6D, 0.049 pg/ml/cc; P=0.0416, 0.007 and 0.0005, respectively). In receiver operating characteristic analyses, the areas under the curves for HGFD (0.64) and IL-6D (0.68) were significantly greater than those for HGF (0.52) and IL-6 (0.61) (P=0.0006 and 0.019, respectively). With an HGFD cutoff value of 0.00392 ng ml−1 cm−3 (sensitivity=100%, specificity=11%), 11.1% of the benign group were able to avoid unnecessary biopsies without missing prostate cancer. HGF and IL-6 levels in combination with prostate volume were shown to be useful parameters for prostate cancer screening in patients with gray-zone PSA levels.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Stenman UH, Leinonen J, Zhang WM, Finne P . Prostate-specific antigen. Semin Cancer Biol 1999; 9: 83–93.
Kalish J, Cooner WH, Graham Jr SD . Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 1994; 43: 601–606.
Polascik TJ, Oesterling JE, Partin AW . Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 1999; 162: 293–306.
Matsumoto K, Nakamura T . Emerging multipotent aspects of hepatocyte growth factor. J Biochem (Tokyo) 1996; 119: 591–600.
Nishimura K, Kitamura M, Miura H, Takada S, Nonomura N, Takahara S et al. Prostate stromal cell-derived hepatocyte growth factor induces invasion of prostate cancer cell line DU145 through tumor-stromal interaction. Prostate 1999; 41: 145–153.
Nishimura K, Matsumiya K, Miura H, Tsujimura A, Nonomura N, Matsumoto K et al. Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells. Int J Androl 2003; 26: 175–179.
Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989; 250: 607–610.
Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E . Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 1993; 50: 15–19.
Corcoran NM, Costello AJ . Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 2003; 91: 545–553.
Culig Z, Bartsch G, Hobisch A . Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 2002; 197: 231–238.
Naughton M, Picus J, Zhu X, Catalona WJ, Vollmer RT, Humphrey PA . Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol 2001; 165: 1325–1328.
Hashem M, Essam T . Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer. J Egypt Natl Canc Inst 2005; 17: 114–120.
Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ et al. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin in Cancer 2006; 4: 269–274.
Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM . Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001; 58: 1008–1015.
Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6: 2702–2706.
Scorilas A, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros N et al. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Prostate 2003; 54: 220–229.
Mehta PB, Robson CN, Neal DE, Leung HY . Serum keratinocyte growth factor measurement in patients with prostate cancer. J Urol 2000; 164: 2151–2155.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E . Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl J Med 1987; 317: 909–916.
Ung JO, San Francisco IF, Regan MM, DeWolf WC, Olumi AF . The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. J Urol 2003; 169: 130–135.
Basillote JB, Armenakas NA, Hochberg DA, Fracchia JA . Influence of prostate volume in the detection of prostate cancer. Urology 2003; 61: 167–171.
Matlaga BR, Eskew LA, McCullough DL, McCullough DL . Prostate biopsy: indications and technique. J Urol 2003; 169: 12–19.
Emiliozzi P, Scarpone P, DePaula F, Pizzo M, Federico G, Pansadoro A et al. The incidence of prostate cancer in men with prostate-specific antigen greater than 4.0 ng ml−1: a randomized study of 6 versus 12 core transperineal prostate biopsy. J Urol 2004; 171: 197–199.
de Jong KP, van Gameren MM, Bijzet J, Limburg PC, Sluiter WJ, Slooff MJH et al. Recombinant human interleukin-6 induces hepatocyte growth factor production in cancer patients. Scand J Gastroenterol 2001; 36: 636–640.
Coskun U, Bukan N, Sancak B, Günel N, Ozenirler S, Unal A et al. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions. Neoplasma 2004; 51: 209–213.
Gohji K, Nomi M, Egawa S, Morisue K, Takenaka A, Okamoto M et al. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate-specific antigen concentrations. Cancer 1997; 79: 1969–1976.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nishimura, K., Arichi, N., Tokugawa, S. et al. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels. Prostate Cancer Prostatic Dis 11, 258–263 (2008). https://doi.org/10.1038/sj.pcan.4501006
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4501006